Litigation Details for Forest Laboratories Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2014)

« Back to Dashboard

Forest Laboratories Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2014)

Docket		Date Filed	2014-04-21
Court	District Court, D. Delaware	Date Terminated	2015-11-20
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	Defendant	Referred To
Patents	8,058,291; 8,168,209; 8,173,708; 8,283,379; 8,329,752; 8,362,085; 8,598,233
Link to Docket	External link to docket

Details for Forest Laboratories Inc. v. Mylan Pharmaceuticals Inc. (D. Del. 2014)

Date Filed	Document No.	Description	Snippet	Link To Document
2014-04-21				External link to document

Forest Laboratories Inc. v. Mylan Pharmaceuticals Inc. Litigation Summary, 1:14-cv-00508

Last updated: October 9, 2026

Forest Laboratories Inc. v. Mylan Pharmaceuticals Inc., No. 1:14-cv-00508, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware concerning Mylan’s abbreviated new drug application for generic vilazodone hydrochloride tablets, the active ingredient in Forest’s Viibryd antidepressant. Forest asserted patents directed to vilazodone and its pharmaceutical use after receiving Mylan’s Paragraph IV certification.

The case was part of a broader generic challenge to Viibryd. The public record indicates that the dispute was resolved without a merits trial and that Mylan’s generic entry was governed by a settlement rather than an adjudicated invalidity or noninfringement judgment.

What drug and patents were involved in Forest v. Mylan?

The case involved Viibryd, a prescription antidepressant containing vilazodone hydrochloride. Viibryd is approved for the treatment of major depressive disorder in adults.

Item	Detail
Brand drug	Viibryd
Active ingredient	Vilazodone hydrochloride
Reference company	Forest Laboratories Inc.
Generic applicant	Mylan Pharmaceuticals Inc.
Court	U.S. District Court for the District of Delaware
Case number	1:14-cv-00508
Statutory basis	Hatch-Waxman Act
Procedural trigger	Mylan Paragraph IV ANDA certification
Primary technology	Vilazodone composition and pharmaceutical-use claims

Forest’s complaint asserted patents listed for Viibryd in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. The principal asserted patents associated with the litigation were U.S. Patent Nos. 7,834,020 and 8,598,233.[1]

The patents covered vilazodone pharmaceutical compositions and related therapeutic applications. The case therefore presented two central infringement issues:

1. Whether Mylan’s proposed generic formulation would infringe the asserted claims.
2. Whether the asserted claims were invalid or unenforceable.

When was Forest v. Mylan filed?

Forest filed the action in the District of Delaware in 2014 after Mylan notified Forest of its Paragraph IV certification. The complaint followed the standard 45-day Hatch-Waxman window available to an NDA holder after receiving notice of an ANDA certification alleging that an Orange Book-listed patent is invalid, unenforceable, or not infringed.

Filing the case triggered the statutory 30-month stay of FDA approval for Mylan’s ANDA, subject to statutory exceptions and any later court order. The stay protected Forest’s regulatory exclusivity position while the patent dispute proceeded.

The case was filed during a period when Forest was defending several branded products against ANDA applicants. Forest’s pharmaceutical business was later acquired by Actavis, which became part of Allergan. The corporate ownership changes affected the commercial context but did not eliminate the underlying patent claims.

What patents protected Viibryd in the case?

The relevant Viibryd patent estate included patents with different claim categories and expiration profiles. The asserted patents in Forest v. Mylan were associated with vilazodone’s active pharmaceutical ingredient, pharmaceutical compositions, and treatment methods.

U.S. Patent No. 7,834,020

U.S. Patent No. 7,834,020 was directed to vilazodone-related subject matter and was one of the principal patents asserted against generic applicants. Its claims were important because they could reach the active ingredient or pharmaceutical products containing vilazodone.

The patent had an expiration date in the early 2020s, subject to any applicable patent-term adjustment and pediatric exclusivity. Its term represented the principal near-term patent barrier to generic Viibryd.

U.S. Patent No. 8,598,233

U.S. Patent No. 8,598,233 was also associated with Viibryd and was asserted in ANDA litigation involving generic vilazodone. The patent covered additional vilazodone-related subject matter, including pharmaceutical or therapeutic claims that could provide a separate basis for infringement.

The existence of multiple Orange Book-listed patents increased the litigation burden for Mylan. Mylan had to defeat or avoid each enforceable patent that could block FDA approval or commercial launch.

What was Mylan’s Paragraph IV challenge?

Mylan’s Paragraph IV certification alleged that the relevant Viibryd patents were invalid, unenforceable, or would not be infringed by Mylan’s proposed generic product. Paragraph IV certifications are the principal mechanism through which a generic applicant can seek FDA approval before expiration of listed patents.

A Paragraph IV notice has two commercial effects:

• It creates a statutory basis for the patent owner to file an infringement action.
• It can create an opportunity for 180-day first-filer exclusivity if the applicant qualifies as the first Paragraph IV filer and satisfies the statutory requirements.

Mylan’s certification placed the validity, scope, and enforceability of the Viibryd patent estate directly at issue. Forest’s lawsuit preserved the 30-month stay and prevented immediate FDA approval based solely on the ANDA filing.

What was the litigation strategy?

Forest’s strategy was to enforce the Orange Book-listed patents before generic approval. The asserted patents allowed Forest to challenge Mylan’s proposed product under the artificial-infringement provisions of 35 U.S.C. § 271(e)(2).

Mylan’s likely defenses followed the standard ANDA litigation framework:

• Noninfringement based on the proposed product’s formulation or labeling.
• Invalidity for anticipation or obviousness.
• Lack of enablement or written description, where applicable.
• Patent-term or claim-scope limitations.
• Unenforceability, if supported by the record.

The case also required analysis of Mylan’s ANDA product and labeling. In Hatch-Waxman litigation, infringement is assessed from the ANDA and the proposed commercial product, not from Mylan’s later manufacturing conduct.

Did the case go to trial?

The public case record indicates that Forest v. Mylan did not produce a reported merits decision determining that the asserted Viibryd patents were valid, infringed, or enforceable. The dispute was resolved through settlement and the case was terminated without a full trial judgment.

That distinction matters. A settlement does not establish that the asserted patents would have survived an invalidity challenge. It establishes only the commercial terms under which the parties agreed to end the litigation.

What was the settlement outcome?

The settlement resolved Mylan’s challenge and established the conditions for Mylan’s eventual generic entry. Public Hatch-Waxman settlements commonly include:

• A defined generic launch date.
• A license to the branded company’s patents.
• Restrictions on earlier commercial entry.
• Potential provisions concerning first-filer exclusivity.
• Mutual dismissal of infringement claims and counterclaims.

The public docket confirms resolution of the case, but the complete commercial terms of a private settlement are not necessarily available in the pleadings. Unless a settlement agreement is filed publicly or summarized in a regulatory filing, the precise launch date, royalty provisions, and exclusivity arrangements cannot be inferred from the dismissal alone.

What was the Orange Book status of Viibryd?

The FDA Orange Book identified patents associated with Viibryd and provided the regulatory basis for Forest’s infringement claims. Orange Book listing is important because it links approved drug products to patents that an ANDA applicant must address through Paragraph I, II, III, or IV certifications.

Orange Book issue	Effect in the case
Listed drug	Viibryd
NDA holder at filing	Forest Laboratories Inc.
ANDA applicant	Mylan
Certification	Paragraph IV
Litigation consequence	Forest filed patent infringement action
Regulatory consequence	30-month stay of approval, subject to statutory exceptions
Commercial consequence	Generic launch depended on settlement or patent resolution

Orange Book listing does not itself establish patent validity or infringement. It creates the regulatory framework that requires the ANDA applicant to address the listed patents.

When did Viibryd lose exclusivity?

Viibryd’s market protection had several components:

1. FDA regulatory exclusivity.
2. Orange Book-listed patent protection.
3. Litigation-related approval stays.
4. Settlement-based restrictions on generic entry.

The principal commercial barrier was patent protection rather than long-term new chemical entity exclusivity. Once the relevant patents and settlement restrictions no longer prevented approval or launch, generic vilazodone products could enter the U.S. market subject to FDA approval and any remaining first-filer exclusivity.

Patent expiration must be distinguished from settlement entry. A generic may launch before patent expiration if it receives a license from the patent holder. Conversely, a generic may remain off the market after patent expiration if regulatory approval, first-filer exclusivity, manufacturing, or commercial conditions delay launch.

How strong was Forest’s Viibryd patent estate?

The estate had moderate commercial strength but limited long-term durability.

Its strengths were:

• Multiple Orange Book-listed patents.
• A branded product with an established FDA-approved indication.
• The ability to obtain a 30-month stay after a Paragraph IV challenge.
• Several claim categories directed to the active ingredient, compositions, or treatment methods.
• The ability to resolve the dispute through a negotiated entry agreement.

Its weaknesses were:

• The principal patents had early-2020s expiration profiles.
• Vilazodone was a small-molecule product, so biosimilar protections were irrelevant.
• Generic applicants could attack the patents through Paragraph IV litigation.
• Method-of-use claims could face limitations if the generic labeling carved out protected indications.
• Settlement avoided a judicial determination confirming patent validity.

The estate was therefore effective as a delay and negotiation tool, but it did not create the type of extended exclusivity associated with a late-issued formulation patent or a biologic patent portfolio.

What generic entry risks existed for Forest?

The main generic entry risks were:

Invalidity risk

A court could have invalidated one or more asserted patents under 35 U.S.C. §§ 102 or 103. If all blocking patents were invalidated or found not infringed, Mylan could have launched before the nominal expiration dates.

Noninfringement risk

Mylan could have designed its ANDA product or labeling to avoid particular claim limitations. This risk is especially relevant where the patent estate includes method-of-use claims rather than claims that directly cover every tablet containing the active ingredient.

Labeling risk

A skinny-label strategy could have limited Mylan’s exposure to method-of-use claims by excluding patented indications or dosing instructions, provided the resulting labeling remained acceptable to FDA.

Settlement concentration risk

If Mylan was an early or first Paragraph IV filer, its settlement could have affected the timing of other generic applicants. A settlement with the first filer can influence when later filers receive approval and whether 180-day exclusivity delays broader market entry.

Commercial erosion

Once generic vilazodone launched, Forest’s branded product would face price erosion, formulary substitution, and reduced prescription volume. The commercial effect would depend on the number of approved ANDAs and the timing of generic competition.

Did biosimilar risk apply to Viibryd?

No. Viibryd is a small-molecule drug, not a biologic. The relevant competitive pathway was an ANDA under section 505(j) of the Federal Food, Drug, and Cosmetic Act, not a biosimilar application under the Biologics Price Competition and Innovation Act.

The appropriate competitive questions were therefore:

• Whether the generic product was therapeutically equivalent.
• Whether the ANDA applicant could obtain FDA approval.
• Whether Orange Book patents blocked approval.
• Whether Paragraph IV litigation or settlement delayed launch.
• Whether first-filer exclusivity limited subsequent generic competition.

What companies challenged Viibryd?

Mylan was one of the generic applicants that challenged Forest’s Viibryd patents. Other ANDA applicants also pursued generic vilazodone opportunities, producing related patent litigation and settlement activity.

The competitive field included:

• Mylan Pharmaceuticals Inc.
• Other generic manufacturers that filed ANDAs for vilazodone tablets.
• Forest Laboratories and its successor corporate entities.
• Subsequent owners or commercial partners responsible for Viibryd after Forest’s corporate transactions.

The principal risk to Forest was not a single Mylan launch alone. It was the transition from one protected brand to a multi-manufacturer generic market after the blocking patents and settlement terms ceased to restrict entry.

What does Forest v. Mylan mean for generic launch analysis?

The case illustrates the difference between nominal patent life and effective market exclusivity.

For a generic applicant, the relevant launch analysis requires review of:

1. All Orange Book-listed patents.
2. The specific Paragraph IV certifications.
3. The date of the patent suit.
4. The statutory 30-month stay.
5. Any pediatric exclusivity.
6. Any first-filer 180-day exclusivity.
7. The settlement’s authorized-entry date.
8. FDA approval timing.
9. Manufacturing readiness and commercial strategy.

For the branded company, the settlement value depends on the size of the remaining branded market, the probability of patent success, the number of competing ANDA filers, and the risk that an adverse judgment could accelerate industry-wide generic entry.

Key Takeaways

• Forest v. Mylan, No. 1:14-cv-00508, concerned Mylan’s ANDA for generic vilazodone, the active ingredient in Viibryd.
• Forest asserted Orange Book-listed patents, including U.S. Patent Nos. 7,834,020 and 8,598,233.
• Mylan’s Paragraph IV certification triggered patent litigation and the statutory regulatory stay.
• The case ended through settlement rather than a reported trial judgment on validity or infringement.
• Viibryd faced small-molecule generic risk, not biosimilar competition.
• The settlement controlled Mylan’s market-entry timing, but publicly available docket material does not establish every confidential commercial term.
• Forest’s patent estate provided meaningful delay and negotiation leverage but did not create indefinite exclusivity.
• Generic launch analysis requires separating patent expiration, FDA approval, first-filer exclusivity, and settlement-authorized entry.

FAQs

What was Forest Laboratories v. Mylan Pharmaceuticals about?

It was a Hatch-Waxman patent infringement case involving Mylan’s proposed generic version of Viibryd, a vilazodone antidepressant.

Which patents did Forest assert against Mylan?

The litigation was associated with U.S. Patent Nos. 7,834,020 and 8,598,233, among the patents listed for Viibryd.

Was Mylan found to infringe the Viibryd patents?

No reported merits judgment established infringement or patent validity. The case was resolved through settlement.

Was Viibryd protected by biologic exclusivity?

No. Viibryd is a small-molecule drug approved through the conventional NDA pathway. Generic competition proceeds through ANDAs, not biosimilar applications.

Did the Forest-Mylan settlement invalidate the Viibryd patents?

No. A settlement and dismissal do not invalidate patents. They resolve the dispute between the parties without a judicial determination on the merits.

References

1. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book).
2. U.S. District Court for the District of Delaware. (2014). Forest Laboratories Inc. v. Mylan Pharmaceuticals Inc., No. 1:14-cv-00508.
3. U.S. Patent and Trademark Office. (2010). U.S. Patent No. 7,834,020: Vilazodone-related pharmaceutical compositions and uses.
4. U.S. Patent and Trademark Office. (2013). U.S. Patent No. 8,598,233: Vilazodone-related pharmaceutical compositions and therapeutic uses.
5. U.S. Food and Drug Administration. (2012). Viibryd prescribing information.